Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: Final results of CALGB (Alliance) 10301, a multicentre phase II study

Peter M. Voorhees, Robert Z. Orlowski, Flora Mulkey, Peter Watson, Susan Geyer, Ben L. Sanford, Elizabeth Bennett, Asher A Chanan Khan, Clara D. Bloomfield, Richard A. Larson

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Long-term outcomes and updated clinical efficacy and safety data were evaluated for newly-diagnosed multiple myeloma patients treated on a phase II study of bortezomib and pegylated liposomal doxorubicin (PegLD). Out of 61 patients, the overall response rate was 57% and the near-complete/complete response rate was 7%. Patients aged ≥65 years old had a higher incidence of treatment-related ≥Grade 3 non-haematological toxicity (80% vs. 51%, P = 0·020). Median overall survival was 5·6 years and negatively impacted by the presence of International Staging System stage III disease, underscoring the need for novel treatment strategies for this group of patients.

Original languageEnglish (US)
Pages (from-to)373-377
Number of pages5
JournalBritish Journal of Haematology
Volume171
Issue number3
DOIs
StatePublished - Nov 1 2015

Fingerprint

Multiple Myeloma
Safety
Survival
Bortezomib
liposomal doxorubicin
Incidence
Therapeutics

Keywords

  • Anthracyclines
  • International staging system
  • Multiple myeloma
  • Proteasome inhibitors

ASJC Scopus subject areas

  • Hematology

Cite this

Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib : Final results of CALGB (Alliance) 10301, a multicentre phase II study. / Voorhees, Peter M.; Orlowski, Robert Z.; Mulkey, Flora; Watson, Peter; Geyer, Susan; Sanford, Ben L.; Bennett, Elizabeth; Chanan Khan, Asher A; Bloomfield, Clara D.; Larson, Richard A.

In: British Journal of Haematology, Vol. 171, No. 3, 01.11.2015, p. 373-377.

Research output: Contribution to journalArticle

Voorhees, Peter M. ; Orlowski, Robert Z. ; Mulkey, Flora ; Watson, Peter ; Geyer, Susan ; Sanford, Ben L. ; Bennett, Elizabeth ; Chanan Khan, Asher A ; Bloomfield, Clara D. ; Larson, Richard A. / Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib : Final results of CALGB (Alliance) 10301, a multicentre phase II study. In: British Journal of Haematology. 2015 ; Vol. 171, No. 3. pp. 373-377.
@article{5a59df072b4e4791b39a58d19d81a45b,
title = "Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: Final results of CALGB (Alliance) 10301, a multicentre phase II study",
abstract = "Long-term outcomes and updated clinical efficacy and safety data were evaluated for newly-diagnosed multiple myeloma patients treated on a phase II study of bortezomib and pegylated liposomal doxorubicin (PegLD). Out of 61 patients, the overall response rate was 57{\%} and the near-complete/complete response rate was 7{\%}. Patients aged ≥65 years old had a higher incidence of treatment-related ≥Grade 3 non-haematological toxicity (80{\%} vs. 51{\%}, P = 0·020). Median overall survival was 5·6 years and negatively impacted by the presence of International Staging System stage III disease, underscoring the need for novel treatment strategies for this group of patients.",
keywords = "Anthracyclines, International staging system, Multiple myeloma, Proteasome inhibitors",
author = "Voorhees, {Peter M.} and Orlowski, {Robert Z.} and Flora Mulkey and Peter Watson and Susan Geyer and Sanford, {Ben L.} and Elizabeth Bennett and {Chanan Khan}, {Asher A} and Bloomfield, {Clara D.} and Larson, {Richard A.}",
year = "2015",
month = "11",
day = "1",
doi = "10.1111/bjh.13592",
language = "English (US)",
volume = "171",
pages = "373--377",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib

T2 - Final results of CALGB (Alliance) 10301, a multicentre phase II study

AU - Voorhees, Peter M.

AU - Orlowski, Robert Z.

AU - Mulkey, Flora

AU - Watson, Peter

AU - Geyer, Susan

AU - Sanford, Ben L.

AU - Bennett, Elizabeth

AU - Chanan Khan, Asher A

AU - Bloomfield, Clara D.

AU - Larson, Richard A.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Long-term outcomes and updated clinical efficacy and safety data were evaluated for newly-diagnosed multiple myeloma patients treated on a phase II study of bortezomib and pegylated liposomal doxorubicin (PegLD). Out of 61 patients, the overall response rate was 57% and the near-complete/complete response rate was 7%. Patients aged ≥65 years old had a higher incidence of treatment-related ≥Grade 3 non-haematological toxicity (80% vs. 51%, P = 0·020). Median overall survival was 5·6 years and negatively impacted by the presence of International Staging System stage III disease, underscoring the need for novel treatment strategies for this group of patients.

AB - Long-term outcomes and updated clinical efficacy and safety data were evaluated for newly-diagnosed multiple myeloma patients treated on a phase II study of bortezomib and pegylated liposomal doxorubicin (PegLD). Out of 61 patients, the overall response rate was 57% and the near-complete/complete response rate was 7%. Patients aged ≥65 years old had a higher incidence of treatment-related ≥Grade 3 non-haematological toxicity (80% vs. 51%, P = 0·020). Median overall survival was 5·6 years and negatively impacted by the presence of International Staging System stage III disease, underscoring the need for novel treatment strategies for this group of patients.

KW - Anthracyclines

KW - International staging system

KW - Multiple myeloma

KW - Proteasome inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84944277337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944277337&partnerID=8YFLogxK

U2 - 10.1111/bjh.13592

DO - 10.1111/bjh.13592

M3 - Article

C2 - 26202857

AN - SCOPUS:84944277337

VL - 171

SP - 373

EP - 377

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -